Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• The Janus kinase (JAK) family, comprising JAK1, JAK2, JAK3, and Tyk2, is crucial for cytokine receptor signaling.
• Approved JAK inhibitors like ruxolitinib and tofacitinib highlight the therapeutic potential of targeting this pathway.
• Selective inhibition of specific JAK family members offers a strategy to enhance efficacy and mitigate side effects associated with non-selective inhibitors.

Purpose of the Study:

• To review patent filings for selective JAK1 and Tyk2 inhibitors.
• To contextualize these selective inhibitors within the broader landscape of JAK inhibitor development, including JAK2 and JAK3 inhibitors.
• To assess the therapeutic potential and research momentum for selective JAK1 and Tyk2 inhibitors.

Main Methods:

• Literature review of published patent filings.
• Analysis of patent claims for selective JAK1 and Tyk2 inhibitors.
• Comparative assessment against existing disclosures for JAK2 and JAK3 inhibitors.

Main Results:

• A growing number of patent filings focus on selective JAK1 and Tyk2 inhibitors.
• Potent and highly selective JAK1 inhibitors have been disclosed, with demonstrated clinical efficacy in rheumatoid arthritis.
• Achievable Tyk2 selectivity is indicated by recent patent applications, suggesting potential for understanding its physiological role.

Conclusions:

• Selective JAK1 inhibitors, exemplified by GLPG-0634, show significant promise for treating inflammatory conditions like rheumatoid arthritis.
• Selective Tyk2 inhibitors are emerging, offering opportunities to elucidate Tyk2's physiological functions.
• Patent applications suggest Tyk2 inhibitors hold potential for treating multiple sclerosis and other inflammatory diseases.